1Kramer H,Pieterman RM,Slebos DJ,et al.PET for the evaluation of pleural thickening observed on CT [J].J Nucl Med,2004,45(6):995-998.
2Zhuang H,Pourdehnad M,Lambright ES,et al.Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes [J].J Nucl Med,2001,42(9):1412-1417.
3Belhocine TZ,Daenen F,Duysinx B.Typical appearance of mesothelioma on an F-18 [J].Clin Nucl Med, 2000,25(8):636.
4Benard F,Sterman D,Smith RJ,et al.Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography [J].Chest,1998,114(3):713-722.
5Schneider DB,Clary-Macy C,Challa S,et al.Positron emission tomography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma [J].J Thorac Cardiovasc Surg, 2000,120(1):128-133.
6Gerbaudo VH,Sugarbaker DJ,Britz-Cunningham S,et al.Assessment of malignant pleural mesothelioma with 18F-FDG dual-head gamma-camera coincidence imaging:comparison with histopathology [J].J Nucl Med,2002,43(9):1144-1149.
7Gerbaudo VH,Britz-Cunningham SH,Di Carli MF,et al.Metabolic significance of the pattern,intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma [J].Thorax,2003,58(12):1077-1082.
8Patz Jr EF,Shaffer K,Piwnica-Worms DR,et al.Malignant pleural mesothelioma:value of CT and MR imaging in predicting resectability [J].Am J Roentgenol,1992,159(5):961-966.
9Sugarbaker DJ,Flores RM,Jaklitsch MY,et al.Resection margins,extrapleural nodal status,and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients [J].J Thorac Cardiovasc Surg,1999,117(1):54-65.
10Rusch VW.A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group [J].Lung Cancer,1996,14(1):1-12.
5Centers for Disease Control and Prevention (CDC).Malignant mesothelioma mortality-United State,1999-2005[J].Morb Mortal Wkly Rep.2009,58(15):393-396.
6Bertazzi PA.Descriptive epidemiology of malignant mesotheliona[J].Med Lav,2005,96(4):287-303.
7Testa JR,Carbone M,Hirvonen A,et al.Loss of heterozygosity analysis defines a 3-cM region of 15q commonly deleted in human malignant mesothelioma[J].Cancer Res,1998,58:4505-4509.
8Bocchetta M,Di Resta I,Powers A,et al.Simian virus 40 and the human mesothelium[J].Proc Natl Acad Sci USA,2000,97:10214-10219.
9Procopio A,Strizzi L,Vianale G,et al.Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen[J].Genes Chromosomes Cancer,2000,29:173-179.
10Kane AB.Animal models of malignant mesothelioma[J].Inhal Toxicol,2006,18(12):1001-1004.
